- Home
- CNTX vs UNCY Comparison
CNTX vs UNCY Comparison
Compare CNTX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- UNCY
- Stock Information
- Founded
- CNTX 2015
- UNCY 2016
- Country
- CNTX United States
- UNCY United States
- Employees
- CNTX N/A
- UNCY 22
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- UNCY Health Care
- Exchange
- CNTX Nasdaq
- UNCY Nasdaq
- Market Cap
- CNTX 78.0M
- UNCY 71.3M
- IPO Year
- CNTX 2021
- UNCY 2021
- Fundamental
- Price
- CNTX $0.58
- UNCY $0.58
- Analyst Decision
- CNTX Strong Buy
- UNCY Strong Buy
- Analyst Count
- CNTX 4
- UNCY 4
- Target Price
- CNTX $6.00
- UNCY $6.38
- AVG Volume (30 Days)
- CNTX 164.6K
- UNCY 889.6K
- Earning Date
- CNTX 05-07-2025
- UNCY 05-14-2025
- Dividend Yield
- CNTX N/A
- UNCY N/A
- EPS Growth
- CNTX N/A
- UNCY N/A
- EPS
- CNTX N/A
- UNCY N/A
- Revenue
- CNTX N/A
- UNCY N/A
- Revenue This Year
- CNTX N/A
- UNCY N/A
- Revenue Next Year
- CNTX N/A
- UNCY $1,422.24
- P/E Ratio
- CNTX N/A
- UNCY N/A
- Revenue Growth
- CNTX N/A
- UNCY N/A
- 52 Week Low
- CNTX $0.49
- UNCY $0.20
- 52 Week High
- CNTX $2.75
- UNCY $0.96
- Technical
- Relative Strength Index (RSI)
- CNTX 33.91
- UNCY 49.67
- Support Level
- CNTX $0.49
- UNCY $0.56
- Resistance Level
- CNTX $0.71
- UNCY $0.62
- Average True Range (ATR)
- CNTX 0.08
- UNCY 0.05
- MACD
- CNTX -0.02
- UNCY 0.00
- Stochastic Oscillator
- CNTX 33.31
- UNCY 74.83
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.